Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longboard Pharmaceuticals reports robust financials and optimistic pipeline outlook

Longboard Pharmaceuticals showcases strong financial position and operational support.
Emphasis on unique characteristics and market opportunities of pipeline assets.
Addressing challenges in patient care and market competition for growth.
Optimism and anticipation for future data outcomes and market performance.

Longboard Pharmaceuticals excels in Q2 with breakthrough therapies and strong financial position

Longboard Pharmaceuticals demonstrated strong performance in Q2 2024, with positive data for Bexicaserin and regulatory milestones enhancing their market position.
The company's strengths lie in the success of their lead assets, financial stability, and strategic focus on addressing key market needs.
Challenges include transitioning preclinical success to clinical efficacy, regulatory hurdles, market competition, and maintaining innovation while ensuring compliance.
Opportunities include market expansion through Breakthrough Therapy designation, advancing LP659, leveraging financial strength for growth, and strategic market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longboard Pharmaceuticals Inc shares surged 181% to $16.96 in late-morning trading on Tuesday after the clinical-stage biopharmaceutical company revealed positive topline data from its PACIFIC Study evaluating bexicaserin, which reduced seizures by 53.3% across a population of patients with developmental and epileptic encephalopathies (DEE).  Longboard noted the phase 1b/2a study included 52 patients ages 12 to 65 years old with different seizure disorders, including Lennox-Gastaut syndrome and Dravet syndrome.

Longboard Pharmaceuticals stock soars on seizure drug results

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #DEEs--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The PACIF.

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-clas.

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neur.

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of Developmental and Epileptic Encephalopathies (DEEs), in poster sessions at the 2023 AES Annual Meeting. Longboard will also host a s.

Longboard Pharmaceuticals' Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

The consensus price target hints at a 262.5% upside potential for Longboard Pharmaceuticals, Inc. (LBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to Trade

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Longboard approved the grant of non-qualified stock options to purchase an aggregate of 58,520 shares of its common stock (the “Common Stock”) as inducements material t.

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023. “We look forward to PACIFIC Study topline data in January 2024 evaluating LP352 in people living with Developmental and Epileptic Encephalopathies, or DEEs. We are thrilled with t.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will present at three upcoming investor conferences in November. Conference Details: Event: Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference Details: Presenting in a fireside chat forma.

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in development for the potential treatment of seizures associated with DEEs. Longboard.

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in development for the potential treatment of seizures associated with DEEs. The event will fea.

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will participate in three upcoming investor conferences in September. Conference Details: Event: Citi 18th Annual BioPharma Conference Details: Hosting investor meetings Thursday, September 7, 2023, in Boston, MA Event: H.C. Wainwrig.

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting. Presentation Details: IEC September 2-6, 2023 – Dublin, Ireland Title: A Phase 1 Clinical Study Shows Robust LP3.

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has completed enrollment of its Phase 1b/2a clinical trial, the PACIFIC Study, which is evaluating LP352, an oral, centrally acting 5-HT2C receptor superagonist, in 52 participants with Developmental and Epileptic Encephalopathies (DEEs). The primary objectives of the.

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023. “We have made great progress in the first half of 2023 and look forward to completing enrollment for the PACIFIC Study in the coming weeks resulting in topline data around the end of.

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will present at the BTIG Virtual Biotechnology Conference and the Wedbush Annual PacGrow Healthcare Conference in New York City. Presentation Details: The conference presentations are intended for BTIG and Wedbush clients only. Event Title: BTIG.

Longboard Pharmaceuticals to Present at Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will participate in a fireside chat as part of Cantor Virtual Brain Week on Friday, June 30, 2023, at 11am ET. A webcast of the presentation will be available on the “Events & Presentations” page within the Investors Relations section of Lon.

Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023

Longboard looks like an intriguing play within the biotech sector. The company was spun out of Arena Pharmaceuticals in 2020 - Arena was subsequently acquired by Pfizer in a $6.7bn deal.

Longboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023. “We are pleased with the excitement for the PACIFIC Study as we progress towards full enrollment and prepare for topline Phase 1b/2a data for LP352 in the fourth quarter of 2023. Site.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Longboard Pharmaceuticals, Inc. (LBPH) is on the Move, Here's Why the Trend Could be Sustainable

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard's Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 4:30pm ET.

Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

The mean of analysts' price targets for Longboard Pharmaceuticals, Inc. (LBPH) points to a 208.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Longboard Pharmaceuticals, Inc. (LBPH) Have the Potential to Rally 208.22% as Wall Street Analysts Expect?

The mean of analysts' price targets for Longboard Pharmaceuticals, Inc. (LBPH) points to an 184.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict an 184.81% Upside in Longboard Pharmaceuticals, Inc. (LBPH): Here's What You Should Know

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q4 2022 Results Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Neena Bitritto-Garg - Citigroup Global Markets Josh Schimmer - Evercore ISI Charles Duncan - Cantor Fitzgerald & Co. Laura Chico - Wedbush Securities Yatin Suneja - Guggenheim Securities Patrick Trucchio - H.C. Wainwright & Co., LLC Operator Good day and thank you for standing by.

News for Longboard Pharmaceuticals Stock (LBPH)